Oragenics Inc./$OGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Oragenics Inc.
Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.
Ticker
$OGEN
Sector
Primary listing
AMEX
Employees
3
Headquarters
Website
Oragenics Inc. Metrics
BasicAdvanced
$2.6m
-
-$4.56
1.11
-
Price and volume
Market cap
$2.6m
Beta
1.11
52-week high
$7.60
52-week low
$0.50
Average daily volume
76k
Financial strength
Current ratio
5.636
Quick ratio
4.732
Total debt to equity
2.745
Interest coverage (TTM)
-11.91%
Profitability
Effective tax rate (TTM)
1.37%
Management effectiveness
Return on assets (TTM)
-101.41%
Return on equity (TTM)
-243.94%
Valuation
Price to book
0.31
Price to tangible book (TTM)
0.31
Price to free cash flow (TTM)
-0.139
Free cash flow yield (TTM)
-721.40%
Free cash flow per share (TTM)
-4.287
Growth
Earnings per share change (TTM)
-90.47%
3-year earnings per share growth (CAGR)
-72.24%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Oragenics Inc. stock?
Oragenics Inc. (OGEN) has a market cap of $2.6M as of May 01, 2026.
What is the P/E ratio for Oragenics Inc. stock?
The price to earnings (P/E) ratio for Oragenics Inc. (OGEN) stock is 0 as of May 01, 2026.
Does Oragenics Inc. stock pay dividends?
No, Oragenics Inc. (OGEN) stock does not pay dividends to its shareholders as of May 01, 2026.
When is the next Oragenics Inc. dividend payment date?
Oragenics Inc. (OGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Oragenics Inc.?
Oragenics Inc. (OGEN) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.